Fulcrum Therapeutics (FULC) EBT (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly EBT of -$35.0 million for Q2 2026, up 16.65% year-over-year from -$30.0 million in Q2 2025, and up 29.98% quarter-over-quarter from -$50.0 million in Q1 2026.
Fulcrum Therapeutics (FULC) EBT (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported EBT for 9 consecutive years, with -$35.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, EBT rose 16.65% year-over-year to -$35.0 million; the TTM figure through Jun 2026 stood at -$234.1 million (down 78.59% YoY), while the FY2025 annual figure was -$161.2 million, down 119.71% from the prior year.
- EBT grew to -$35.0 million in Q2 2026 per FULC's latest filing, from -$50.0 million in the prior quarter.
- Across five years, EBT topped out at $40.2 million in Q2 2024 and bottomed at -$94.0 million in Q1 2022.
- Historically, EBT has averaged -$42.8 million across 5 years, with a median of -$41.6 million in 2023.
- Annual changes were most pronounced in 2024 — EBT soared 197.39% — and 2025, when it slumped 236.18%.
- Fulcrum Therapeutics' EBT stood at -$29.9 million in 2022, then slumped by 44.37% to -$43.1 million in 2023, then soared by 41.93% to -$25.0 million in 2024, then plunged by 236.18% to -$84.2 million in 2025, then soared by 58.43% to -$35.0 million in 2026.
- Business Quant data shows FULC's EBT at -$35.0 million in Q2 2026, -$50.0 million in Q1 2026, and -$84.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -34.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.98 Mn |
| Mar 31, 2026 | -49.97 Mn |
| Dec 31, 2025 | -84.15 Mn |
| Sep 30, 2025 | -64.99 Mn |
| Jun 30, 2025 | -41.97 Mn |
| Mar 31, 2025 | -29.43 Mn |
| Dec 31, 2024 | -25.03 Mn |
| Sep 30, 2024 | -25.68 Mn |
| Jun 30, 2024 | 40.22 Mn |
| Mar 31, 2024 | -65.24 Mn |
| Dec 31, 2023 | -43.11 Mn |
| Sep 30, 2023 | -40.26 Mn |
| Jun 30, 2023 | -30.65 Mn |
| Mar 31, 2023 | -30.52 Mn |
| Dec 31, 2022 | -192.46 Mn |
| Sep 30, 2022 | -27.08 Mn |
| Jun 30, 2022 | -35.44 Mn |
| Mar 31, 2022 | -94.00 Mn |
| Dec 31, 2021 | -50.95 Mn |
| Sep 30, 2021 | -96.47 Mn |